Drug Metabolism Reviews最新文献

Metabolism and detection of designer benzodiazepines: a systematic review. 特制苯并二氮杂卓的代谢和检测；系统综述。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-10-14 DOI: 10.1080/03602532.2024.2410747

Prince S Gameli, Marilyn A Huestis, Aurora Balloni, Francesco P Busardò, Jeremy Carlier

{"title":"Metabolism and detection of designer benzodiazepines: a systematic review.","authors":"Prince S Gameli, Marilyn A Huestis, Aurora Balloni, Francesco P Busardò, Jeremy Carlier","doi":"10.1080/03602532.2024.2410747","DOIUrl":"10.1080/03602532.2024.2410747","url":null,"abstract":"Synthesis and illicit use of designer benzodiazepines are growing concerns, with these new psychoactive substances (NPS) posing serious health consequences and new hurdles for toxicologists. Consumption marker identification and characterization is paramount in confirming their use. The benzodiazepine core structure is a fusion of benzene and a seven-membered heterocycle with two nitrogen atoms forming the diazepine ring. Minor variations on the core structure produce different classes of benzodiazepines with marked differences in physiological effects. The present review provides a comprehensive designer benzodiazepines metabolism overview and suggests suitable human consumption biomarkers for toxicology casework. A systematic literature search of PubMed®, ScopusTM, Web of ScienceTM, and Cochrane databases was conducted independently by two coauthors adhering to PRISMA guidelines. Data from 30 in vitro and in vivo models of designer benzodiazepines metabolism from January 2007 to February 2023 were included. 1,4-benzodiazepines (n = 10), 2,3-benzodiazepines (n = 1), triazolo-benzodiazepines (n = 9), and thieno-triazolo-benzodiazepines (n = 3) study design, sample pretreatment, analytical techniques, and major metabolites detected in various matrices are addressed. Metabolites following hydroxylation and phase II glucuronide conjugation were the most prevalent analytes. N-Glucuronidation of parent azole-fused benzodiazepines, and nitro-reduced and N-acetylated metabolites of nitro-containing designer benzodiazepines were also common. From these data, we propose a generic metabolic pathway for designer benzodiazepines. The sporadic illicit market presents challenges in toxicological casework and necessitates comprehensive biomarker investigations, especially in cases with legal implications. There are few metabolism data for many designer benzodiazepines, emphasizing the need for research focusing on closing these gaps.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role and current research status of resveratrol in the treatment of osteoarthritis and its mechanisms: a narrative review. 白藜芦醇在骨关节炎治疗中的作用和研究现状及其机制：综述。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-10-08 DOI: 10.1080/03602532.2024.2402751

Xiongfei Zou, Hongjun Xu, Wenwei Qian

{"title":"The role and current research status of resveratrol in the treatment of osteoarthritis and its mechanisms: a narrative review.","authors":"Xiongfei Zou, Hongjun Xu, Wenwei Qian","doi":"10.1080/03602532.2024.2402751","DOIUrl":"https://doi.org/10.1080/03602532.2024.2402751","url":null,"abstract":"Osteoarthritis (OA) is a chronic degenerative disease caused by various factors such as aging, obesity, trauma, and genetics. It is a challenging condition faced by orthopedic doctors in clinical practice and places a heavy burden on patients and their families. Currently, the treatment of OA primarily focuses on symptomatic relief and lacks ideal therapeutic methods. Resveratrol is a natural polyphenolic compound with anti-inflammatory and antioxidant properties, and in recent years, it has gained attention as a candidate drug for OA treatment. This article provides an overview of the research status on the role and mechanisms of resveratrol in treating OA. It has been found that resveratrol can prevent the development of OA by inhibiting inflammatory responses, protecting chondrocytes, maintaining cartilage homeostasis, promoting autophagy, and has shown certain therapeutic effects. This process may be related to the regulation of signaling pathways such as nuclear factor-kappa B (NF-κB), Toll-like receptor 4 (TLR4), and silent information regulator 1 (SIRT1). We summarize the current molecular mechanisms of resveratrol in treating OA, hoping to provide a reference for further research and application of resveratrol in OA treatment.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug metabolism and transport mediated the hepatotoxicity of Pleuropterus multiflorus root: a review. 药物代谢和转运介导的多花蛇床子根肝毒性：综述。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-10-01 DOI: 10.1080/03602532.2024.2405163

Zhaoquan Wu, Dangang Shangguan, Qi Huang, Yi-Kun Wang

引用次数: 0

Drug transporters in drug disposition - highlights from the year 2023. 药物处置中的药物转运体--2023 年的亮点。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-09-11 DOI: 10.1080/03602532.2024.2399523

Paresh P Chothe, Upendra A Argikar, Pallabi Mitra, Masanori Nakakariya, Diane Ramsden, Charles J Rotter, Philip Sandoval, Kimio Tohyama

{"title":"Drug transporters in drug disposition - highlights from the year 2023.","authors":"Paresh P Chothe, Upendra A Argikar, Pallabi Mitra, Masanori Nakakariya, Diane Ramsden, Charles J Rotter, Philip Sandoval, Kimio Tohyama","doi":"10.1080/03602532.2024.2399523","DOIUrl":"10.1080/03602532.2024.2399523","url":null,"abstract":"Drug transporter field is rapidly evolving with significant progress in in vitro and in vivo tools and, computational models to assess transporter-mediated drug disposition and drug-drug interactions (DDIs) in humans. On behalf of all coauthors, I am pleased to share the fourth annual review highlighting articles published and deemed influential in the field of drug transporters in the year 2023. Each coauthor independently selected peer-reviewed articles published or available online in the year 2023 and summarized them as shown previously (Chothe et al. 2021; Chothe et al. 2022, 2023) with unbiased perspectives. Based on selected articles, this review was categorized into four sections: (1) transporter structure and in vitro evaluation, (2) novel in vitro/ex vivo models, (3) endogenous biomarkers, and (4) PBPK modeling for evaluating transporter DDIs (Table 1). As the scope of this review is not to comprehensively review each article, readers are encouraged to consult original paper for specific details. Finally, I appreciate all the authors for their time and continued support in writing this review.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions. 对药物遗传学、药物-基因相互作用以及药物-药物-基因相互作用的见解。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-08-18 DOI: 10.1080/03602532.2024.2385928

Laura E Russell, Katrina G Claw, Kaja M Aagaard, Sarah M Glass, Kuheli Dasgupta, F Leah Nez, Alex Haimbaugh, Benjamin J Maldonato, Jaydeep Yadav

{"title":"Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions.","authors":"Laura E Russell, Katrina G Claw, Kaja M Aagaard, Sarah M Glass, Kuheli Dasgupta, F Leah Nez, Alex Haimbaugh, Benjamin J Maldonato, Jaydeep Yadav","doi":"10.1080/03602532.2024.2385928","DOIUrl":"https://doi.org/10.1080/03602532.2024.2385928","url":null,"abstract":"This review explores genetic contributors to drug interactions, known as drug-gene and drug-drug-gene interactions (DGI and DDGI, respectively). This article is part of a mini-review issue led by the International Society for the Study of Xenobiotics (ISSX) New Investigators Group. Pharmacogenetics (PGx) is the study of the impact of genetic variation on pharmacokinetics (PK), pharmacodynamics (PD), and adverse drug reactions. Genetic variation in pharmacogenes, including drug metabolizing enzymes and drug transporters, is common and can increase the risk of adverse drug events or contribute to reduced efficacy. In this review, we summarize clinically actionable genetic variants, and touch on methodologies such as genotyping patient DNA to identify genetic variation in targeted genes, and deep mutational scanning as a high-throughput in vitro approach to study the impact of genetic variation on protein function and/or expression in vitro. We highlight the utility of physiologically based pharmacokinetic (PBPK) models to integrate genetic and chemical inhibitor and inducer data for more accurate human PK simulations. Additionally, we analyze the limitations of historical ethnic descriptors in pharmacogenomics research. Altogether, the work herein underscores the importance of identifying and understanding complex DGI and DDGIs with the intention to provide better treatment outcomes for patients. We also highlight current barriers to wide-scale implementation of PGx-guided dosing as standard or care in clinical settings.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanisms of intestinal pharmacokinetic natural product-drug interactions. 肠道药代动力学天然产品与药物相互作用的机制。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-08-12 DOI: 10.1080/03602532.2024.2386597

Victoria O Oyanna, John D Clarke

{"title":"Mechanisms of intestinal pharmacokinetic natural product-drug interactions.","authors":"Victoria O Oyanna, John D Clarke","doi":"10.1080/03602532.2024.2386597","DOIUrl":"10.1080/03602532.2024.2386597","url":null,"abstract":"The growing co-consumption of botanical natural products with conventional medications has intensified the need to understand potential effects on drug safety and efficacy. This review delves into the intricacies of intestinal pharmacokinetic interactions between botanical natural products and drugs, such as alterations in drug solubility, permeability, transporter activity, and enzyme-mediated metabolism. It emphasizes the importance of understanding how drug solubility, dissolution, and osmolality interplay with botanical constituents in the gastrointestinal tract, potentially altering drug absorption and systemic exposure. Unlike reviews that focus primarily on enzyme and transporter mechanisms, this article highlights the lesser known but equally important mechanisms of interaction. Applying the Biopharmaceutics Drug Disposition Classification System (BDDCS) can serve as a framework for predicting and understanding these interactions. Through a comprehensive examination of specific botanical natural products such as byakkokaninjinto, green tea catechins, goldenseal, spinach extract, and quercetin, we illustrate the diversity of these interactions and their dependence on the physicochemical properties of the drug and the botanical constituents involved. This understanding is vital for healthcare professionals to effectively anticipate and manage potential natural product-drug interactions, ensuring optimal patient therapeutic outcomes. By exploring these emerging mechanisms, we aim to broaden the scope of natural product-drug interaction research and encourage comprehensive studies to better elucidate complex mechanisms.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs). 表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）的肝毒性。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-08-09 DOI: 10.1080/03602532.2024.2388203

Lulin Zhu, Xinxin Yang, Shanshan Wu, Rong Dong, Youyou Yan, Nengming Lin, Bo Zhang, Biqin Tan

{"title":"Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs).","authors":"Lulin Zhu, Xinxin Yang, Shanshan Wu, Rong Dong, Youyou Yan, Nengming Lin, Bo Zhang, Biqin Tan","doi":"10.1080/03602532.2024.2388203","DOIUrl":"10.1080/03602532.2024.2388203","url":null,"abstract":"Drug-induced liver injury (DILI) is one of the most frequently adverse reactions in clinical drug use, usually caused by drugs or herbal compounds. Compared with other populations, cancer patients are more prone to abnormal liver function due to primary or secondary liver malignant tumor, radiation-induced liver injury and other reasons, making potential adverse reactions from liver damage caused by anticancer drugs of particular concernduring clinical treatment process. In recent years, the application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has changed the treatment status of a series of solid malignant tumors. Unfortunately, the increasing incidence of hepatotoxicitylimits the clinical application of EGFR-TKIs. The mechanisms of liver injury caused by EGFR-TKIs were complex. Despite more than a decade of research, other than direct damage to hepatocytes caused by inhibition of cellular DNA synthesis and resulting in hepatocyte necrosis, the rest of the specific mechanisms remain unclear, and few effective solutions are available. This review focuses on the clinical feature, incidence rates and the recent advances on the discovery of mechanism of hepatotoxicity in EGFR-TKIs, as well as rechallenge and therapeutic strategies underlying hepatotoxicity of EGFR-TKIs.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic. 酶介导的药物间相互作用：体内和体外方法、监管指南和临床转化综述。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-07-26 DOI: 10.1080/03602532.2024.2381021

Jaydeep Yadav, Benjamin J Maldonato, Joseph M Roesner, Ana G Vergara, Erickson M Paragas, Theresa Aliwarga, Sara Humphreys

{"title":"Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic.","authors":"Jaydeep Yadav, Benjamin J Maldonato, Joseph M Roesner, Ana G Vergara, Erickson M Paragas, Theresa Aliwarga, Sara Humphreys","doi":"10.1080/03602532.2024.2381021","DOIUrl":"10.1080/03602532.2024.2381021","url":null,"abstract":"Enzyme-mediated pharmacokinetic drug-drug interactions can be caused by altered activity of drug metabolizing enzymes in the presence of a perpetrator drug, mostly via inhibition or induction. We identified a gap in the literature for a state-of-the art detailed overview assessing this type of DDI risk in the context of drug development. This manuscript discusses in vitro and in vivo methodologies employed during the drug discovery and development process to predict clinical enzyme-mediated DDIs, including the determination of clearance pathways, metabolic enzyme contribution, and the mechanisms and kinetics of enzyme inhibition and induction. We discuss regulatory guidance and highlight the utility of in silico physiologically-based pharmacokinetic modeling, an approach that continues to gain application and traction in support of regulatory filings. Looking to the future, we consider DDI risk assessment for targeted protein degraders, an emerging small molecule modality, which does not have recommended guidelines for DDI evaluation. Our goal in writing this report was to provide early-career researchers with a comprehensive view of the enzyme-mediated pharmacokinetic DDI landscape to aid their drug development efforts.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bioactivation and reactivity research advances - 2023 year in review. 生物活化和反应研究进展--2023 年回顾。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-07-17 DOI: 10.1080/03602532.2024.2376023

Shuai Wang, Upendra A Argikar, Maria Chatzopoulou, Sungjoon Cho, Rachel D Crouch, Deepika Dhaware, Ting-Jia Gu, Carley J S Heck, Kevin M Johnson, Amit S Kalgutkar, Joyce Liu, Bin Ma, Grover P Miller, Jessica A Rowley, Herana Kamal Seneviratne, Donglu Zhang, S Cyrus Khojasteh

{"title":"Bioactivation and reactivity research advances - 2023 year in review.","authors":"Shuai Wang, Upendra A Argikar, Maria Chatzopoulou, Sungjoon Cho, Rachel D Crouch, Deepika Dhaware, Ting-Jia Gu, Carley J S Heck, Kevin M Johnson, Amit S Kalgutkar, Joyce Liu, Bin Ma, Grover P Miller, Jessica A Rowley, Herana Kamal Seneviratne, Donglu Zhang, S Cyrus Khojasteh","doi":"10.1080/03602532.2024.2376023","DOIUrl":"10.1080/03602532.2024.2376023","url":null,"abstract":"Advances in the field of bioactivation have significantly contributed to our understanding and prediction of drug-induced liver injury (DILI). It has been established that many adverse drug reactions, including DILI, are associated with the formation and reactivity of metabolites. Modern methods allow us to detect and characterize these reactive metabolites in earlier stages of drug development, which helps anticipate and circumvent the potential for DILI. Improved in silico models and experimental techniques that better reflect in vivo environments are enhancing predictive capabilities for DILI risk. Further, studies on the mechanisms of bioactivation, including enzyme interactions and the role of individual genetic differences, have provided valuable insights for drug optimizations. Cumulatively, this progress is continually refining our approaches to drug safety evaluation and personalized medicine.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolism of new drug modalities research advances - 2023 year in review. 新药代谢研究进展 - 2023 年回顾。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2024-07-05 DOI: 10.1080/03602532.2024.2370331

Bin Ma, Upendra A Argikar, Lionel Cheruzel, Sungjoon Cho, Simon Hauri, Kevin M Johnson, Joyce Liu, Simone Schadt, Shuai Wang, S Cyrus Khojasteh

引用次数: 0